title: Megestrol acetate in breast cancer--a panel discussion.
abstract: Physicians have been using hormonal manipulation to treat advanced breast cancer for almost a century. Surgical ablation of the ovaries, adrenals, and pituitary glands has achieved remarkable tumor regression in sensitive patients. Alternatively, large doses of estrogens, progestins, and androgens have achieved similar results. More recently, the emergence of new therapies, such as antiestrogens, LHRH agonists, and chemical blockade of adrenal steroid biosynthesis offer additional choices. Within limits, all of these therapies are equally effective in sensitive patients. The trend at the present time is to select a therapy that will produce a good response with minimal toxicity. Here the participating physicians will discuss one such therapy-Megace (megestrol acetate). They will consider the role of Megace in the treatment of advanced breast cancer along with issues such as toxicity, dose response, etc.
authors.affiliation: University of Texas Health Science Center, San Antonio 78284.
authors.forename: W L
authors.initials: WL
authors.lastname: McGuire
authors.forename: P A
authors.initials: PA
authors.lastname: Johnson
authors.forename: H B
authors.initials: HB
authors.lastname: Muss
authors.forename: C K
authors.initials: CK
authors.lastname: Osborne
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008535:Megestrol / Q000494:pharmacology / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000187:drug effects* / Q000502:physiology; D011980:Receptors, Progesterone / Q000187:drug effects* / Q000502:physiology
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D008535:Megestrol